What Elica M Treats: Main Uses and Benefits

The medication may be part of symptomatic management in clinical settings that involve acute or disruptive symptom patterns, addressing skin conditions where inflammation is concurrent with a fungal pathogen. The product is commonly used to help with tinea infections (ringworm, athlete's foot, jock itch) and is relevant for easing associated symptoms. It is applied in situations where additional symptomatic support is needed for acute or disruptive episodes of fungal dermatitis.

It is relevant in conditions characterized by periods of heightened symptoms, such as tinea infections that involve significant inflammatory manifestations. It may assist with managing symptoms related to inflammatory or irritative states, such as intense itching, significant redness, and swelling. This provides supportive relief when symptoms interfere with routine activities.

“The medication is commonly used when symptoms cluster into patterns requiring short-term symptomatic assistance to prevent the escalation of discomfort.”

The primary benefit is that it helps address symptom clusters that interfere with daily functioning, contributing to improved comfort during periods of heightened symptoms, in situations involving conditions like tinea corporis, tinea cruris, and severely inflamed tinea pedis.

---

Quick Fact: Supportive Role in Managing Inflammatory Symptoms

This medication is generally considered relevant in contexts marked by increased discomfort where short-term symptomatic assistance is needed to manage pronounced cutaneous inflammation and associated pruritus (itching).

Regulatory References

1. Label: Miconazole Nitrate 2% Cream - DailyMed

Elica M is a prescription medicine, and official regulatory information strictly defines the patient populations who may and must not use it.

Populations Who Must Not Use Elica M (Contraindications)

Use of Elica M is strictly contraindicated for individuals who have a known hypersensitivity or allergy to the active ingredients, Mometasone Furoate and Miconazole Nitrate, or any other component of the formulation. The medicine is also contraindicated if the treatment area is affected by certain viral skin infections (including Herpes Simplex, Varicella/Chickenpox, or Vaccinia), Tuberculosis, or Syphilis.

Age, Physiological Status, and Restricted Use

• Pediatric Age: Use of the cream is not recommended for children under 2 years of age due to an increased risk of systemic absorption and potential for side effects. For children 2 years and older, use is generally limited in duration.
• Pregnancy and Lactation: Elica M should not be used during pregnancy due to the potential for fetal effects. Use is not recommended during breastfeeding unless the supervising physician determines the potential benefits outweigh the risks.
• Conditions Requiring Caution: Patients with pre-existing conditions like Cushing's syndrome or Diabetes must use the medicine with caution, as systemic absorption of the corticosteroid component may worsen these conditions.

Interactions with other medicines and products

Official regulatory documents emphasize that the systemic drug interaction profile for Elica M (Mometasone Furoate/Miconazole Nitrate topical cream) is primarily relevant due to the Miconazole Nitrate component. The risk, although considered low due to the topical route of administration, is linked to Miconazole’s capacity to inhibit certain Cytochrome P450 (CYP) enzymes.

Official Regulatory Interaction Profile

Interaction Type	Affected Product/Class	Regulatory Requirement
Exposure Modification	Oral Anticoagulants (e.g., Warfarin)	Careful monitoring of anticoagulant effect (e.g., INR) is required.
Metabolic Inhibition	Other CYP3A4/2C9 Substrates	Caution advised, as effects may be increased.

This need for monitoring stems from Miconazole's ability to inhibit CYP3A4 and CYP2C9, enzymes that metabolize these systemic medications. Inhibiting these enzymes can potentially lead to an increase in the blood concentration and effect of the co-administered drug, such as Warfarin. Regulators advise caution specifically with other CYP substrates, including oral hypoglycaemics and phenytoin, as their effects can also be increased.

No systemic drug combinations are formally listed as contraindicated, and no timing separation requirements are explicitly documented for this topical product.

Elica M is a fixed-dose combination product containing Mometasone Furoate and Miconazole Nitrate, which exert their actions via two distinct pharmacological targets.

Mometasone Furoate is a synthetic corticosteroid that functions as an agonist at the intracellular glucocorticoid receptor (GR). Upon binding to the GR in the cytoplasm, the complex translocates to the nucleus. Here, it modulates gene transcription by binding to glucocorticoid response elements (GREs) in the promoter region of target genes, both upregulating the expression of anti-inflammatory molecules, such as lipocortin, and downregulating the expression of pro-inflammatory mediators, including cytokines, chemokines, and adhesion molecules, via inhibition of transcription factors like NF-kappaB. This leads to reduced production and release of inflammatory cellular components, resulting in systemic-level vasoconstriction and modulation of the cutaneous immune response.

Miconazole Nitrate is an azole antifungal that acts as a non-competitive inhibitor of cytochrome P450 14alpha-demethylase (CYP51), a key enzyme in the fungal cell membrane synthesis pathway. The inhibition of CYP51 blocks the demethylation of lanosterol to ergosterol. The resulting accumulation of lanosterol and depletion of ergosterol disrupts the structural integrity and functional permeability of the fungal cell membrane, leading to molecular and intracellular dysfunction. This directly modulates the survival and proliferation of susceptible fungi.

How to Use Elica M: Official Administration Guidelines

This section describes the instructions for administering Elica M (Mometasone Furoate and Miconazole Nitrate) Topical Cream. These guidelines define the proper application technique, frequency, and specific restrictions to ensure compliant use.

---

Administration Scope

Instruction	Detail
Route of Administration	Topical (External Skin Use Only).
Dosing Schedule	Apply a thin film of cream to the affected area.
Frequency	Typically applied once daily; application may be permitted once or twice daily.
Preparation	The affected area should be cleaned and dried before application.
Special Conditions	Do not use with occlusive dressings (e.g., tight bandages, plastic pants/diapers) unless directed by a physician.

---

Procedural Structure and Course Duration

Prescribing information outlines a standardized application sequence:

1. Clean and dry the affected skin area.
2. Apply a small amount of the cream as a thin film to the entire affected area.
3. Rub the cream in gently until the cream has disappeared.
4. Wash hands immediately after application (unless treating the hands).

Treatment should be discontinued when control of the condition is achieved, rather than after a fixed number of days. If there is no improvement in the condition within 7 days, a healthcare professional should be consulted.

---

Population-Specific Limits

Specific limitations are established for certain groups:

• Pediatric Patients: Use is not recommended for children below 2 years of age. For treatment on a child's face, the duration should be limited to no more than 5 days.
• Older Adults: The cream should be used sparingly, and use may be limited to a few weeks.

Research evidence / Overview of Studies for Elica M

Evidence Overview for Inflamed Tinea Infections (Fungal Infections)

The evidence supporting the study of combination creams containing both a topical corticosteroid (like Mometasone Furoate) and an antifungal agent (like Miconazole Nitrate) is primarily derived from systematic reviews and regulatory consensus surrounding this specific class of medication. Research examined skin conditions characterized by superficial fungal infections (tinea) and significant inflammation and irritation. Studies in this area were observed in general patient populations. Findings describe patterns observed in the studies related to the changes measured in the fungal component and the surface irritation.

Research Findings for Napkin Dermatitis Complicated by Infection

Research for this specific combination was studied for use in children in the zero to three years of age bracket who had napkin dermatitis complicated by fungal or bacterial infection. The research was conducted via open-label, non-randomized Phase IV multicenter studies. Studies monitored changes in clinical signs and symptoms, and the evidence describes patterns observed in the studies related to how symptoms evolved in the observed populations over a short time interval.

What the Research Landscape Identifies as Uncertain or Missing

Comparative evidence is lacking in widely published literature for this specific combination, specifically large-scale studies that compare it directly against the single-agent antifungal (Miconazole). The follow-up durations were limited in many studies, typically assessing changes over 7 to 14 days. This means that long-term outcomes are not fully established. Data for certain special populations, such as older adults or patients with significant underlying comorbidities, remain insufficient.

Key Studies & References

1. Label: Miconazole Nitrate 2% Cream Antifungal - DailyMed - NIH (Used for Miconazole Monotherapy Context and Regulatory Constraints)

Common questions about Elica M (FAQ)

---

Q: How long is the treatment course for Elica M?

According to official product information, treatment should be discontinued once the condition is under control. The use of potent topical corticosteroids is generally limited to short courses, often no more than a few weeks. If no improvement in the treated area is observed within 7 days, a healthcare professional should be consulted.

---

Q: What are the less common side effects of Elica M?

Common side effects listed include a mild burning, stinging, or itching sensation at the application site. Regulatory documents indicate that less common reactions, or those where the frequency is not known, can include issues like skin thinning (atrophy), stretch marks (striae), dryness, or changes in skin color (hypopigmentation).

---

Q: How does the steroid (Mometasone) work to reduce inflammation?

The Mometasone component is a corticosteroid used to target signs and symptoms of inflammation, redness, and itching. Once absorbed by the skin cells, it works by intervening in the body's chemical processes that initiate the inflammatory response.

---

Q: What are the long-term safety concerns of using Elica M?

The main safety concern with prolonged use is the risk of the medicine being absorbed into the body (systemic absorption). Official warnings note that this can potentially lead to serious conditions, such as the suppression of the body's natural stress hormones (HPA axis suppression) or manifestations of Cushing's syndrome.

---

Q: Is Elica M available over-the-counter or only by prescription?

Regulatory authorities classify Elica M, which contains the potent topical corticosteroid Mometasone Furoate and the antifungal Miconazole Nitrate, as a Prescription-Only Medicine (POM).

---

Q: How quickly can I expect to see an improvement in my skin condition?

Clinical information suggests that visible improvement in the skin condition is typically observed within the first week of use. If improvement has not been noticed after 7 days of treatment, a healthcare professional should be consulted.

---

Q: Can Elica M be applied to open wounds or broken skin?

Regulatory guidelines advise that this medication is intended only for use on external skin surfaces. The cream should not be applied to skin areas that have cuts, scrapes, open wounds, or burns, as this may increase the amount of medicine absorbed into the body.

---

Q: What should I do if I accidentally swallow Elica M?

In the event that Elica M cream is accidentally swallowed, first-aid measures recommend NOT inducing vomiting. The mouth should be rinsed thoroughly with water, and immediate medical attention should be sought.

How to Store and Dispose of Elica M Cream

The storage and disposal requirements for Elica M (Mometasone/Miconazole) are defined by regulatory documents to maintain product quality and safety.

Requirement	Official Instruction
Storage Temperature	Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).
Handling & Protection	Protect the cream from freezing, excessive heat, and moisture.
Packaging	Keep the product in the original container and use it before the expiration date.
Child Safety	Keep out of reach of children at all times.
Disposal	Do not dispose of unused or expired medicine by flushing it down a toilet or pouring it down a drain. Follow local guidelines or a drug take-back program for proper disposal.